NCT03824678View on ClinicalTrials.gov

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

June 18, 2019

Study Completion Date

June 18, 2019

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

CC-220

CC-220

Trial Locations (3)

32809

Orlando Clinical Research Center OCRC, Orlando

78215

The Texas Liver Institute, San Antonio

33014-3616

Clinical Pharmacology of Miami, LLC, Miami

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY